Clioquinol: Review of its mechanisms of action and clinical uses in neurodegenerative Disorders

CNS Neuroscience and Therapeutics

Volumn 18, Issue 1, 2012, Pages 41-46

  Bareggi, Silvio R ^a   Cornelli, Umberto ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Alzheimer disease; Anticancer; Antioxidant activity; Huntington disease; Ionophore; Metal chelation; Prion disease

Indexed keywords

AMYLOID; ANTINEOPLASTIC AGENT; CHELATING AGENT; CLIOQUINOL; COPPER; GLUCURONIC ACID; IRON; SULFATE; ZINC;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CHELATION THERAPY; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; ELECTROCHEMICAL DETECTION; ELECTRON CAPTURE DETECTION; ENTEROPATHY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS FRAGMENTOGRAPHY; METABOLISM; METABOLITE; NONHUMAN; OXIDATION; PARKINSON DISEASE; REVIEW; SUBACUTE MYELOOPTIC NEUROPATHY; ULTRAVIOLET RADIATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; CLIOQUINOL; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84856280358     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00231.x     Document Type: Review

References (59)

1. Tateishi J. Subacute myelo-optic-neuropathy: Clioquinol intoxication in humans and animals. Neuropathology 2000;20(Suppl):520-524.
2. Tsubaki T, Honma Y, Hoshi M. Neurological syndrome associated with clioquinol. Lancet 1971;1:696-697.
3. Gilland O. A neurological evaluation of purported cases of SMON in Sweden. Acta Neurol Scand Suppl 1984;100:165-169.
4. Helmut L. Neuroscience. An antibiotic to treat Alzheimer's?Science 2000;290:1273-1274.
5. Meade TW. Subacute myelo-optic neuropathy and clioquinol. Br J Prev Soc Med 1975;29:157-169.
6. Cuajungo MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann N Y Acad Sci 2000;920:292-304.
7. Huckle R. PBT-1 Prana Biotechnology. Curr Opin Invest Drugs 2005;6:99-107.
8. Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 2008;15:223-240. Very interesting concerning the mechanisms of ALZ disease: Zn precipitates Aβ and Cu stabilises it and, in this environment, clioquinol and derivatives may act as ionophores and not as chelators.
9. Hayakawa K, Kitada K, Hamaki M, Miyazaki M. HPLC determination of clioquinol and its conjugates in biological materials. J Chromatogr 1982;229:159-165.
10. Kotaki H, Yamamura Y, Tanimura Y, Saitoh Y, Nakagawa F, Tamura Z. Intestinal absorption and metabolism of clioquinol in the rat. J Pharm Dyn 1983;6:881-887.
11. Ezzedeen FW, Sthos SJ, Stublar M. Analysis of iodochlorhydroxyquin in biological materials by HPLC. J Chromatogr 1983;276:121-128.
12. Jack B, Riess W. Pharmacokinetics of iodochlorhydroxyquin in man. J Pharm Sci 1973;62:1929-1932. Interesting description of clioquinol kinetics in humans.
13. Chen Clioquinol-T, Kodama H, Egashira Y, Samejima K, Imanari T, Tamura Z. A GC determination method of 5-chloro-7-iodo-8-quinolinol and its conjugates in biological fluids. Chem Pharm Bull 1976;24:2007-2013.
14. Matsuki Y, Kukuhara K, Abe M, Othaki T, Nambara T. Determination of chinoform in biological fluids and nervous tissues of the dog by GC-MS. Arch Toxicol 1987;59:374-378.
15. Rizk M, Belal F, Ibrahim F, Ahmed S, Sheribah ZA. LC of pharmaceutically halogenated 8-hydroxyquinolines after precolumn derivatization with Pd (II). J Pharm Biomed Anal 2002;27:813-820.
16. Bondiolotti GP, Pollera C, Pirola R, Bareggi SR. Determination of clioquinol in plasma and tissues of hamsters by HPLC and electrochemical detection. J Chromatogr B 2006;837:87-91. An interesting new analytical method.
17. Chen L-T, Kodama H, Egashira Y, Samejima K, Imanari T, Tamura Z. Serum levels of 5-chloro-7-iodo-8-quinolinol and its toxicity in various animals. Chem Pharm Bull 1976;24:2007-2013.
18. Hayashi M, Fuwa T, Awazu S, Hanano M. Differences in species of iodochlorohydoxyquin absorption, metabolism and excretion. Chem Pharm Bull 1976;24:2589-2596. Interesting description of correlations between concentrations and toxicity.
19. Hayashi M, Fuwa T, Awazu S, Hanano M. Various factors affecting intestinal absorption of iodochlorhydroxyquin in rat and man. Chem Pharm Bull 1976;24:2603-2609.
20. Bondiolotti GP, Sala M, Pollera C, Gervasoni M, Puricelli M, Ponti W, Bareggi SR. Pharmacokinetics and distribution of clioquinol in golden hamsters. J Pharm Pharmacol 2007;59:387-393.
21. Ezzedeen FW, Stohs SJ, Kilzer KL, Makoid MC, Ezzedeen NW. Percutaneous absorption and disposition of iodochlorhydroxyquin in dogs. J Pharm Sci 1984;73:1369-1372.
22. Committee on Drugs. Clioquinol (lodochlorhydroxyquin, Vioform) and lodoquinol (Diiodohydroxyquin): Blindness and Neuropathy. Pediatrics 1990;86:797-798.
23. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003;26:207-214.
24. Igata A, Hasegawa S, Tsuji T. On the green pigment found in SMON patients: Two cases excreting greenish urine. Jap Med J 1970;2427:25.
25. Takasu T, Igata A, Toyokura Y. On the green tongue observed in SMON patients. Igakuno Ayumi 1970;72:539.
26. Arbisier JL, Kraeft SK, van Leewen R, et al. Clioquinol-zinc chelate: A candidate agent of subacute myelo-optic neuropathy. Mol Med 1998;4:665-670.
27. Mao X, Scimmer AD. The toxicology of Clioquinol. Toxicol Lett 2008;182:1-6. Toxicological effects in animals and humans.
28. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000;4:184-191.
29. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits b-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676. Interesting description of the drug's mechanism of action on amyloid.
30. Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zinc in plaques of the Swedish mutant beta-amylodosis precursor protein transgenic mice. J Neurosci 1999:19:RC10.
31. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-9868.
32. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52n.
33. Suh SW, Jensen KB, Jensen MS, et al. Histochemically reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000;852:274-278.
34. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999;274:23223-23228.
35. Filitz G, Price KA, Caragounis A, Du T, Crouch PJ, White AR. The role of metals in modulating metalloprotease activity in the AD brain. Eur Biophys J 2008;37:315-321. Studies of animals and cell cultures suggesting that increasing intracellular Cu levels can improve AD-like disease.
36. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid β peptide. Biochim Biophys 2007;1768:1976-1980.
37. Teiber C, Simons A, Strauss M, et al. Clioquinol mediates copper uptake and counteract Cu efflux activities of the amyloid precursor protein of Alzheimer disease. J Biol Chem 2004;279:51958-51964.
38. Atamna H, Frey WH. A role for heme in Alzheimer's disease: Heme binding amyloid β and has altered metabolism. Proc Natl Acad Sci USA 2004;101:11153-11158.
39. House E, Collingwood J, Kan A, Kochazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheim Dis 2004;6:291-301.
40. Rumschik SM, Nydegger I, Zhao J, Kay AR. The interplay between inorganic phosphate and aminoacids determines zinc solubility in rat brain slices. J Neurochem 2009;108:1300-1308. Study showing that inorganic phosphate limits extracellular Zn concentration by inducing metal precipitation.
41. Yoshiike Y, Tanemura K, Murayama O, et al. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J Biol Chem 2001;276:32293-32299.
42. Takasu T. SMON - a model of the iatrogenic disease. Rinsho Shinkeigaku. 2003;43:866-869.
43. Ha L, Ryu J, Park CB. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry 2007;46:6118-6125.
44. 42 in senile plaque cores in Alzheimer's disease. J Alzheim Dis 2006;10:173-177.
45. Benvenisti-Zarom L, Chen J, Regan RF. The oxidative neurotoxicity of clioquinol. Neuro Pharmac 2004;49:687-694.
46. Barnham Kj, Cappai R, Beyreuther K, Masters CL, Hill AF. Delinetaing common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci 2006;31:465-472.
47. Formentin E, Puricelli M, Pollera C, Ponti W. Evaluation of Clioquinol activity towards transmissible spongiform encephalopathies (TSE) in cellular models and cell-free systems. Vet Res Commun 2006;30:253-255.
48. Bareggi SR, Braida D, Pollera C, et al. Effects of clioquinol on memory impairment and the neurochemical modifications induced by scrapie infection in golden hamsters. Brain Res 2009;1280:195-200. Describes the effects of clioquinol on TSE.
49. Brown DR. Neurodegeneration and oxidative stress: Prion disease results from loss of antioxidant defence. Folia Neuropathol 2005;43:229-243.
50. Pollera C, Lucchini B, Formentin E, Bareggi S, Poli G, Ponti W. Evaluation of anti-prionic activity of clioquinol in an in vivo model (Mesocricetus auratus). Vet Res Commun 2005;29(Suppl 2):253-255.
51. Seetharam SV, Prudencio M, Karch C, Holloway SP, Borchelt DR, Hart PJ. Immature copper-zinc superoxide dismutase and familial amyotrophic sclerosis. Exp Biol Med 2009;234:1140-1154.
52. Mattson MP. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci 2004;1012:37-50.
53. Nguyen, T, Hamby, A, Massa, SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;16:11840-11845.
54. Ding W-Q, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic Clioquinol. Cancer Res 2005;65:3389-3395. Describes the drug's activity as an anticancer agent.
55. Ding WQ, Yu HJ, Lind SE. Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett 2008;271:251-259.
56. Yassin MS, Ekblom J, Löfberg C, Oreland L. Transmethylation reactions and autoradiographic distribution of vitamin B12: Effects of clioquinol treatment in mice. Jpn J Pharmacol 1998;78:55-56. Interesting description of toxic mechanism.
57. Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 2001;12:408-414. The clinical efficacy of clioquinol in AD.
58. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with clioquinol targeting Abeta amyloid deposition and toxicity in Alzheimer's disease: A pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-1691. The effects of clioquinol in ALZ patients with moderate AD.
59. Sampson EL, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2007;3, DOI: An interesting review indicating that there is a lack of evidence as to whether clioquinol has any positive clinical benefit in patients with AD.